1. Product
Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for
Study
1.2.3. Key Market
Segmentations
2. Research
Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive
Summary
3.1. Overview of the
Market
3.2. Overview of Key
Market Segmentations
3.3. Overview of Key
Market Players
3.4. Overview of Key
Regions/Countries
3.5. Overview of Market
Drivers, Challenges, Trends
4. Voice
of Customer
5. Clinical
Trial Analysis
5.1. Ongoing
Clinical Trials
5.2. Completed
Clinical Trials
5.3. Terminated
Clinical Trials
5.4. Breakdown
of Pipeline, By Development Phase
5.5. Breakdown
of Pipeline, By Status
5.6. Breakdown
of Pipeline, By Study Type
5.7. Breakdown
of Pipeline, By Region
5.8. Clinical
Trials Heat Map
6.
Global Vulvovaginal Candidiasis Treatment
Market Outlook
6.1. Market
Size & Forecast
6.1.1. By
Value
6.2. Market
Share & Forecast
6.2.1.
By Drug Class (Clotrimazole, Nystatin,
Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others)
6.2.2.
By Route of Administration (Oral, Intravenous,
Topical)
6.2.3.
By Distribution Channel (Hospital Pharmacy,
Retail Pharmacy, Online Pharmacy)
6.2.4.
By Region
6.2.5. By
Company (2022)
6.3. Market
Map
6.3.1. By
Drug Class
6.3.2. By
Route of Administration
6.3.3. By
Distribution Channel
6.3.4. By
Region
7.
North America Vulvovaginal Candidiasis Treatment
Market Outlook
7.1. Market
Size & Forecast
7.1.1. By
Value
7.2. Market
Share & Forecast
7.2.1.
By Drug Class
7.2.2.
By Route of Administration
7.2.3.
By Distribution Channel
7.2.4. By
Country
7.3. North
America: Country Analysis
7.3.1. United
States Vulvovaginal Candidiasis Treatment Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Drug Class
7.3.1.2.2.
By Route of Administration
7.3.1.2.3.
By Distribution Channel
7.3.2. Canada
Vulvovaginal Candidiasis Treatment Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Drug Class
7.3.2.2.2.
By Route of Administration
7.3.2.2.3.
By Distribution Channel
7.3.3. Mexico
Vulvovaginal Candidiasis Treatment Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Drug Class
7.3.3.2.2.
By Route of Administration
7.3.3.2.3.
By Distribution Channel
8.
Europe Vulvovaginal Candidiasis Treatment
Market Outlook
8.1. Market
Size & Forecast
8.1.1. By
Value
8.2. Market
Share & Forecast
8.2.1.
By Drug Class
8.2.2.
By Route of Administration
8.2.3.
By Distribution Channel
8.2.4.
By Country
8.3. Europe:
Country Analysis
8.3.1. France
Vulvovaginal Candidiasis Treatment Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Drug Class
8.3.1.2.2.
By Route of Administration
8.3.1.2.3.
By Distribution Channel
8.3.2. Germany
Vulvovaginal Candidiasis Treatment Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Drug Class
8.3.2.2.2.
By Route of Administration
8.3.2.2.3.
By Distribution Channel
8.3.3. United
Kingdom Vulvovaginal Candidiasis Treatment Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Drug Class
8.3.3.2.2.
By Route of Administration
8.3.3.2.3.
By Distribution Channel
8.3.4. Italy
Vulvovaginal Candidiasis Treatment Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Drug Class
8.3.4.2.2.
By Route of Administration
8.3.4.2.3.
By Distribution Channel
8.3.5. Spain
Vulvovaginal Candidiasis Treatment Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Drug Class
8.3.5.2.2.
By Route of Administration
8.3.5.2.3.
By Distribution Channel
9.
Asia-Pacific Vulvovaginal Candidiasis
Treatment Market Outlook
9.1. Market
Size & Forecast
9.1.1. By
Value
9.2. Market
Share & Forecast
9.2.1.
By Drug Class
9.2.2.
By Route of Administration
9.2.3.
By Distribution Channel
9.2.4. By
Country
9.3. Asia-Pacific:
Country Analysis
9.3.1. China
Vulvovaginal Candidiasis Treatment Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Drug Class
9.3.1.2.2.
By Route of Administration
9.3.1.2.3.
By Distribution Channel
9.3.2. India
Vulvovaginal Candidiasis Treatment Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Drug Class
9.3.2.2.2.
By Route of Administration
9.3.2.2.3.
By Distribution Channel
9.3.3. Japan
Vulvovaginal Candidiasis Treatment Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Drug Class
9.3.3.2.2.
By Route of Administration
9.3.3.2.3.
By Distribution Channel
9.3.4. South
Korea Vulvovaginal Candidiasis Treatment Market Outlook
9.3.4.1.
Market Size & Forecast
9.3.4.1.1.
By Value
9.3.4.2.
Market Share & Forecast
9.3.4.2.1.
By Drug Class
9.3.4.2.2.
By Route of Administration
9.3.4.2.3.
By Distribution Channel
9.3.5. Australia
Vulvovaginal Candidiasis Treatment Market Outlook
9.3.5.1.
Market Size & Forecast
9.3.5.1.1.
By Value
9.3.5.2.
Market Share & Forecast
9.3.5.2.1.
By Drug Class
9.3.5.2.2.
By Route of Administration
9.3.5.2.3.
By Distribution Channel
10. South
America Vulvovaginal Candidiasis Treatment Market Outlook
10.1.
Market Size & Forecast
10.1.1. By
Value
10.2.
Market Share & Forecast
10.2.1.
By Drug Class
10.2.2.
By Route of Administration
10.2.3.
By Distribution Channel
10.2.4. By
Country
10.3.
South America: Country Analysis
10.3.1. Brazil
Vulvovaginal Candidiasis Treatment Market Outlook
10.3.1.1. Market
Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market
Share & Forecast
10.3.1.2.1.
By Drug Class
10.3.1.2.2.
By Route of Administration
10.3.1.2.3.
By Distribution Channel
10.3.2. Argentina
Vulvovaginal Candidiasis Treatment Market Outlook
10.3.2.1. Market
Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market
Share & Forecast
10.3.2.2.1.
By Drug Class
10.3.2.2.2.
By Route of Administration
10.3.2.2.3.
By Distribution Channel
10.3.3. Colombia
Vulvovaginal Candidiasis Treatment Market Outlook
10.3.3.1. Market
Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market
Share & Forecast
10.3.3.2.1.
By Drug Class
10.3.3.2.2.
By Route of Administration
10.3.3.2.3.
By Distribution Channel
11. Middle
East and Africa Vulvovaginal Candidiasis Treatment Market Outlook
11.1.
Market Size & Forecast
11.1.1. By
Value
11.2.
Market Share & Forecast
11.2.1.
By Drug Class
11.2.2.
By Route of Administration
11.2.3.
By Distribution Channel
11.2.4. By
Country
11.3.
MEA: Country Analysis
11.3.1. South
Africa Vulvovaginal Candidiasis Treatment Market Outlook
11.3.1.1. Market
Size & Forecast
11.3.1.1.1.
By Value
11.3.1.2. Market
Share & Forecast
11.3.1.2.1.
By Drug Class
11.3.1.2.2.
By Route of Administration
11.3.1.2.3.
By Distribution Channel
11.3.2. Saudi
Arabia Vulvovaginal Candidiasis Treatment Market Outlook
11.3.2.1. Market
Size & Forecast
11.3.2.1.1.
By Value
11.3.2.2. Market
Share & Forecast
11.3.2.2.1.
By Drug Class
11.3.2.2.2.
By Route of Administration
11.3.2.2.3.
By Distribution Channel
11.3.3. UAE
Vulvovaginal Candidiasis Treatment Market Outlook
11.3.3.1. Market
Size & Forecast
11.3.3.1.1.
By Value
11.3.3.2. Market
Share & Forecast
11.3.3.2.1.
By Drug Class
11.3.3.2.2.
By Route of Administration
11.3.3.2.3.
By Distribution Channel
12. Market
Dynamics
12.1.
Drivers
12.2.
Challenges
13. Market
Trends & Developments
13.1.
Recent Developments
13.2.
Mergers & Acquisitions
13.3.
Product Launches
14. Competitive
Landscape
14.1.
Business Overview
14.2.
Product Offerings
14.3.
Recent Developments
14.4.
Financials (As Reported)
14.5.
Key Personnel
14.6.
SWOT Analysis
14.6.1. Astellas
Pharma Inc.
14.6.2. Mycovia
Pharmaceuticals, Inc.
14.6.3. Basilea
Pharmaceutica Ltd.
14.6.4. Scynexis,
Inc.
14.6.5. Grupo
Ferrer Internacional, S.A.
14.6.6. Pfizer,
Inc.
14.6.7. Pacgen
Life Science Corporation
14.6.8. NovaDigm
Therapeutics, Inc.
14.6.9. Cidara
Therapeutics, Inc.
14.6.10.
Amplyx Pharmaceuticals Inc.
15. Strategic
Recommendations